Neurotechnology

Brain-computer interfaces (BCIs) are evolving from science fiction to a booming market, with both invasive and non-invasive approaches gaining traction. While invasive implants target severe disabilities, non-invasive BCIs aim for broader consumer adoption. AI is crucial for interpreting brain signals, and the field sees significant investment, particularly in the U.S. and China. Companies like BrainCo are leading non-invasive BCI development, focusing on accessible and affordable solutions for prosthetics, sleep aids, and future consumer electronics, while navigating investment and geopolitical landscapes.

ONWARD Medical has implanted its investigational ARC-BCI® Therapy in seven individuals, a significant milestone in brain-computer interface technology for spinal cord injury. This system integrates a brain implant, AI for signal decoding, and a neurostimulator to translate intended movement into functional limb motion. The therapy has received FDA Breakthrough Device Designation and is supported by substantial research grants. Further clinical trials are planned to establish broader efficacy and safety.

Neuralink, Elon Musk’s brain-computer interface company, plans a major expansion, aiming to implant BCI chips in 20,000 patients annually by 2031, generating $1 billion in revenue. The company intends to establish five clinics in six years, developing “Telepathy,” “Blindsight,” and “Deep” implants for communication, vision restoration, and neurological disorder treatment. US approval for “Telepathy” is expected by 2029, with “Blindsight” launching in 2030. Neuralink, valued at $9 billion, has secured $1.3 billion in funding.